Skye Bioscience Advances Nimacimab Trial with Cohort 2 Approval
Event summary
- Skye Bioscience's Cohort Review Committee approved the opening of Cohort 2 in its CBeyond Part C Expansion Study based on favorable safety data from the first four participants in Cohort 1.
- Cohort 2 will test a higher dose (600 mg IV) of nimacimab compared to Cohort 1's 400 mg IV.
- The study comprises two cohorts with 8 participants each, randomized in a 3:1 ratio to nimacimab or placebo.
- No neuropsychiatric adverse events have been reported to date with the 400 mg IV dose.
The big picture
Skye Bioscience's progression to Cohort 2 in its nimacimab trial underscores the company's focus on developing next-generation molecules for metabolic health. The approval highlights the potential of nimacimab as a peripheral CB1 inhibitor with a favorable safety profile, positioning it as a potential complement to existing GLP-1 therapies like Wegovy. The study's design and the CRC's approval reflect a strategic approach to dose escalation and safety assessment, which is critical in the competitive landscape of obesity and metabolic disorder treatments.
What we're watching
- Safety Profile
- How the higher dose in Cohort 2 will affect the safety profile of nimacimab, particularly regarding neuropsychiatric adverse events.
- Clinical Progress
- The pace at which Skye Bioscience can advance through subsequent cohorts and generate preliminary safety and PK data.
- Commercial Potential
- Whether nimacimab's superior safety profile versus small molecule CB1 inhibitors will translate into commercial differentiation.
Related topics